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Recent outbreaks of viral hemorrhagic fevers (VHFs), including Ebola virus disease (EVD) and
Lassa fever (LF), highlight the urgent need for sensitive, deployable tests to diagnose these
devastating human diseases. Here we develop CRISPR-Cas13a-based (SHERLOCK) diag-
nostics targeting Ebola virus (EBOV) and Lassa virus (LASV), with both fluorescent and
lateral flow readouts. We demonstrate on laboratory and clinical samples the sensitivity of
these assays and the capacity of the SHERLOCK platform to handle virus-specific diagnostic
challenges. We perform safety testing to demonstrate the efficacy of our HUDSON protocol
in heat-inactivating VHF viruses before SHERLOCK testing, eliminating the need for an
extraction. We develop a user-friendly protocol and mobile application (HandLens) to report
results, facilitating SHERLOCK’s use in endemic regions. Finally, we successfully deploy our
tests in Sierra Leone and Nigeria in response to recent outbreaks.
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Ebola virus (EBOV) and Lassa virus (LASV) pose immediate,severe threats to human life and public health, as demon-strated by ongoing outbreaks of EBOV disease (EVD) in the
Democratic Republic of the Congo (DRC) and Lassa fever (LF) in
Nigeria. Despite their high morbidity and mortality, EVD and LF
are difficult to diagnose, because early symptoms, including fever,
vomiting, and aches, are often indistinguishable from those of
more common tropical diseases1–3. Rapid point-of-care diag-
nostics are vital for facilitating timely clinical care and proper
containment4.
Despite the critical need for rapid point-of-care diagnostics for
these viruses, current gold standards lack the logistical feasibility
to effectively diagnose cases in endemic regions with limited
infrastructure. PCR-based diagnostics are sensitive and can be
rapidly developed for emerging or mutating viruses but they are
not practical as a point-of-care test, as they require advanced
laboratory infrastructure, a cold chain, and expensive reagents.
Rapid antigen- and antibody-based tests are deployable but are
less sensitive than PCR and take longer to develop; they can also
be ineffective in the early/acute stage of infection5–7, a critical
period for supportive care and to contain human-to-human
spread.
EBOV and LASV both present distinct diagnostic challenges.
The live attenuated rVSVΔG-ZEBOV-GP EBOV vaccine (Merck),
currently being deployed to combat the DRC outbreak, produces
EBOV GP RNA that can yield false-positive tests by glycoprotein
(GP)-targeting assays, including the commonly used GeneXpert
reverse-transcriptase quantitative PCR (RT-qPCR)8–10; similar
false positives will be a concern whenever new live attenuated
vaccines are introduced for any virus. In the case of LASV, high
genetic diversity in the virus through western Africa hinders the
development of diagnostic tools sensitive to all viral strains. The
most widely used diagnostic for LF viral detection, a RT-qPCR
developed against Josiah strains derived from Sierra Leone (clade
IV), has had false-positive and false-negative results when tested
against recent clade II samples from Nigeria11,12.
The recently developed CRISPR-based SHERLOCK (Specific
High-sensitivity Enzymatic Reporter unLOCKing) platform pro-
vides a promising approach for rapidly adaptable, deployable
diagnostics. SHERLOCK utilizes the RNA-targeting protein
Cas13a for sensitive and specific detection of viral nucleic
acid13,14. It pairs isothermal recombinase polymerase amplifica-
tion (RPA) with crRNA-guided Cas13a detection, which enables
specific pairing of Cas13a with the target sequence and signal
amplification via Cas13’s collateral cleavage activity13,15,16. Both
amplification and Cas13a-based detection are isothermal,
requiring only a low-energy, single-temperature heat block and
basic pipette and tips, compatible with point-of-care detection.
SHERLOCK can be combined with HUDSON (Heating Unex-
tracted Diagnostic Samples to Obliterate Nucleases), which
inactivates pathogens and releases nucleic acid through a com-
bined heat and chemical denaturation, eliminating the need for a
column- or bead-based nucleic acid extraction14. Our recent work
has shown the high sensitivity of SHERLOCK and HUDSON in
detecting Zika virus and dengue virus directly from bodily
fluids14, allowing for a fully point-of-care diagnostic. Utilizing
this system, we develop a diagnostic test for EBOV and LASV that
can be deployed in any setting, requires minimal processing of
infectious materials, and accurately reports test results in a user-
friendly format.
Results
CRISPR-Cas13a diagnostic development and validation for
VHFs. Motivated by the increased severity and frequency of
EBOV and LASV outbreaks, we describe here the development
and validation of SHERLOCK assays to detect these viruses. The
assays can be detected by two readout methods, either fluores-
cence or lateral flow. The more sensitive fluorescence-based sys-
tem allowed us to perform extensive validation during the
development of our assay, determine the length of amplification
time needed for viral detection, and determine the limit of
detection (LOD). The lateral flow readout, which we then vali-
dated further, utilizes a commercially available detection strip to
provide semi-quantitative point-of-care detection of the virus.
We developed a SHERLOCK EBOV assay to target the L gene
of the EBOV Zaire strain, which accounts for the majority of
known clinical cases of EBOV infections, including the two
largest and most recent EVD epidemics17,18. We used primer
design applications (CATCH19) to identify an optimal target
within a conserved region of the L gene, thus avoiding potential
false-positive results caused by the rVSVΔG-ZEBOV-GP EBOV
vaccine (Fig. 1a and Supplementary Tables 1–3). Our assay
detected synthetic DNA at concentrations as low as 10 copies/µl
using either fluorescent or lateral flow readout (Fig. 1b, c). As
EBOV, LASV, and Marburg virus (MARV) infections present
with similar symptoms and have been known to co-circulate, we
tested for cross-reactivity using seedstock and synthetic DNA of
each virus; our assay showed no cross-reactivity to either LASV or
MARV (Fig. 1d).
We validated the SHERLOCK EBOV assay at the Broad
Institute using 16 clinical samples taken from suspected EVD
patients in Sierra Leone during the 2014–2016 West Africa
outbreak. For safety reasons, we tested complementary DNA
(which is not infectious) and benchmarked the results against
previously generated sequencing data17,20 (Fig. 1e). Of the
16 samples, 12 were positive for EBOV by sequencing, all 12 of
which were positive by SHERLOCK. The four sequencing-
negative samples were negative by SHERLOCK (100% sensitivity,
100% concordance).
We also developed and validated SHERLOCK assays for LASV,
a challenging target because of the virus’s extreme genetic
diversity, both within and especially between clades21. Currently,
two clades—clade II, localized in Nigeria, and clade IV, localized
in Sierra Leone22—account for over 90% of known clinical
infections21,22. Given this extreme genetic diversity, we designed
two LASV SHERLOCK assays (Supplementary Tables 1–3). The
first assay (LASV-II) targets clade II. To ensure detection of all
known genomes in this highly divergent clade, the assay contains
two multiplexed crRNAs (LASV-IIA and LASV-IIB) (Fig. 2a).
When we compared the two LASV-II crRNAs to an alternative
assay with only one crRNA, the former detected LASV more
quickly and identified an additional positive sample (Fig. 2b). The
second assay (LASV-IV) targets clade IV; in this clade, we found a
more conserved region that enabled us to use a single crRNA. The
LASV-II assay was sensitive down to 10 copies/µl with a
fluorescent readout (Supplementary Fig. 1a) and 100 copies/µl
using lateral flow strips (Supplementary Fig. 1c); the LOD for
LASV-IV was 100 copies/µl for the fluorescence-based assay
(Supplementary Fig. 1b) and 1000 copies/µl for the lateral flow
assay (Supplementary Fig. 1d). Neither the LASV-II nor the
LASV-IV assay cross-reacted with synthetic DNA from the other
clade or with known positive patient samples from the other
clade’s geographic region, nor did they cross-react with EBOV or
Marburg seedstock cDNA (Fig. 2c, d). The LASV SHERLOCK
assays are thus both species and clade specific, and therefore
region specific, which can help distinguish possible imported
cases from local transmission.
Deployment of CRISPR-Cas13a diagnostics. Next, we deployed
the EBOV assay to our collaborators in Sierra Leone to test
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patient samples stored from the 2014–2016 outbreak using the
point-of-care lateral flow assay. This allowed us to validate and
assess the practicality of the SHERLOCK assay in a setting with
previously circulating EBOV and limited infrastructure. As a
head-to-head comparison, we identified 4 whole blood (WB) in
trizol aliquots from the same patients tested in our first panel of
16 samples. These samples were stored at the Kenema Govern-
ment Hospital (KGH) biobank under variable temperature con-
ditions (−20 °C with multiple power cuts). Using the same
protocol as for the panel of 16 (Supplementary Fig. 2), all
4 samples were positive by SHERLOCK, consistent with the
results obtained at the Broad Institute (Fig. 1f), despite multiple
years of an imperfect cold chain.
The SHERLOCK EBOV assay was also highly efficient at
detecting a more recent EBOV variant from the DRC. We tested a
synthetic version of a 2018 Ebola isolate from Ituri Province (Ituri
isolate 18FHV089), DRC (Fig. 1g, h), and, as validation, a 2014
Makona isolate from Sierra Leone that underwent the same
synthetic generation process (see “Methods”)23,24. Utilizing both
the SHERLOCK fluorescence-based and lateral flow-based assays,
the Makona and Ituri isolates were both detected at levels down
to 10 copies/µl. The DRC isolate was genetically distinct from the
2014 isolate but maintained the key conserved stretch on the L
gene that the SHERLOCK assay targets, which remains conserved
on all available genomes from the ongoing DRC outbreak.
We also tested our LASV assay in Sierra Leone and Nigeria
using clinical samples. We evaluated the sensitivity on a panel of
ten RNA and cDNA samples per clade, derived from suspected
LF patients (Fig. 2e, g). We compared SHERLOCK results using
both fluorescent and lateral flow readouts head-to-head with the
Nikisin RT-qPCR assay25 and benchmarked both results against
sequencing data (Fig. 2f, h). The LASV-II fluorescent readout was
positive for all seven sequencing-positive samples and negative
for all three sequencing-negative samples (100% sensitivity, 100%
concordance), as was the Nikisin RT-qPCR. The LASV-II lateral
flow readout failed to detect one sequencing-positive sample. For
the LASV-IV assay, SHERLOCK performed significantly better
than RT-qPCR. SHERLOCK was again positive for all seven
sequencing-positive samples (100% sensitivity), whereas the
Nikisin assay was only 40% sensitive and our in-house Broad
RT-qPCR assay (Supplementary Tables 4 and 5), developed on all
recent LASV genomes, was only 50% sensitive. The three
sequencing-negative samples were negative by SHERLOCK
(100% concordance). The low detection rate of clade IV by RT-
qPCRs is likely due to multiple mismatched base pairs where the
primers anneal; despite this, Nikisin continues to be a primary
diagnostic.
Safety analysis and efficacy of heat inactivation. Reducing
exposure to viral hemorrhagic fevers (VHFs) among healthcare
workers is critical for the safe and effective use of diagnostic tests.
For diagnostic test design, this requires ensuring that the sample
is fully inactivated and, where possible, using non-invasive sample
types. To this end, we combined the SHERLOCK assay with the
HUDSON technique, which integrates heat inactivation with
TCEP : EDTA to denature RNAses and release nucleic acid from
viral particles, thus eliminating the need for RNA extraction.
Furthermore, as LASV and EBOV are secreted in saliva and
urine26,27, HUDSON enables disease diagnosis without the need
for an invasive blood draw or specialized equipment, resulting in
a faster end-to-end processing time. To confirm HUDSON’s
efficacy for viral inactivation and to determine the most sensitive
HUDSON protocol for SHERLOCK use, we carried out tests at
the BSL4 laboratory facility at the NIH Integrated Research
Facilities.
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Fig. 1 Detection of EBOV. a Schematic of the SHERLOCK EBOV assay. b, c Detection of a serial dilution of EBOV synthetic DNA using (b) mean
fluorescence of three technical replicates and (c) lateral flow readouts. Error bars indicate ±1 SD for three technical replicates. d Test of cross-reactivity
using MARV, EBOV, and LASV viral seedstock cDNA. Heat map is measured in Fluorescence (a.u.). e SHERLOCK testing of cDNA extracted from 12
confirmed EBOV-positive and 4 confirmed EBOV-negative samples collected from suspected EVD patients during the 2014 outbreak in Sierra Leone. Error
bars indicate 95% confidence interval. f Four of the samples from e were also tested by collaborators using lateral flow detection. g, h Detection of serial
dilution of synthetic RNA from Ituri, DRC and Makona, Sierra Leone using (g) fluorescence where error bars indicate ±1 SD for three technical replicates
and (h) lateral flow readouts carried out at USAMRIID. Source data are in the Source Data file.
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We first showed that HUDSON successfully rendered viruses
inactive in three sample types. We spiked human WB, urine, and
saliva with the live EBOV Mayinga variant and confirmed that
samples had viral activity using an initial plaque assay (Fig. 3a).
Samples underwent serial dilution to mimic variation in viral
load and were then heat and chemical treated using HUDSON.
We performed HUDSON using two conditions, either 95 °C for
10min or 70 °C for 30min, to determine the most effective heat-
inactivation protocol. We used a standard plaque assay, two passages
in Vero cells, to determine presence or absence of replication-
competent virus. After HUDSON treatment, no viable virus was
detected at either temperature, showing complete inactivation at all
e
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concentrations and confirming the safety of the HUDSON-
SHERLOCK platform. To ensure safety, clinical and laboratory staff
should use appropriate personal protective equipment or a glove box
until a sample is fully inactivated.
We then performed SHERLOCK on the HUDSON-inactivated
samples to establish how HUDSON temperature conditions affect
SHERLOCK’s performance. The serially diluted EBOV samples
were tested by SHERLOCK using the lateral flow readout (Fig. 3b)
and the results were compared to the GeneXpert diagnostic. Both
heat-inactivation conditions performed equally. Using our
combined HUDSON-SHERLOCK method, we detected virus
down to 1.1E+ 05 PFU/mL in WB, 1.2E+ 05 PFU/mL in urine,
and 9.4E+ 03 PFU/mL in saliva (Supplementary Table 6). When
considering cycle threshold ≤ 36 as definitive positives28, GeneX-
pert was more sensitive than SHERLOCK for WB (4.4E+
02 PFU/mL) and urine (1.1E+ 02 PFU/mL), but comparable
for saliva (1.1E+ 03 PFU/mL but for only NP detection, 9.4E+
03 PFU/mL for GP detection). Ultimately, our HUDSON testing
highlights the potential to safely and sensitively test saliva in
suspected patients, minimizing the need for more invasive blood
draws and increasing safety for healthcare workers.
HandLens: a mobile application for diagnostic analysis. The
lateral flow readout of the current SHERLOCK protocol can be
Fig. 2 Detection of LASV clade II and IV. a Schematic of LASV SHERLOCK assays targeting the two most common clades of LASV: clades II (LASV-II assay)
and IV (LASV-IV assay). For the LASV-II assay, three crRNAs were designed and tested. Two crRNAs are multiplexed to encompass the clade’s genetic
diversity (IIA/IIB or IIA/IIC). Each crRNA was tested using three technical replicates. b–d Heat maps are measured in fluorescence (a.u.). b Detection of LASV
RNA from suspected LF clinical samples using crRNAs IIA, IIB, IIC, or a combination of crRNAs. c Test of cross-reactivity between different viral species using
MARV, EBOV, and LASV viral seedstock cDNA. The LASV-II and LASV-IV assays do not cross-react with MARV or EBOV seed stocks. d Test of cross-
reactivity between LASV clade-specific assays using clinical samples from recent outbreaks in Nigeria and Sierra Leone. The LASV-II and LASV-IV assays
provide clade-specific detection. e SHERLOCK testing using the LASV-II assay of RNA extracted from seven confirmed LASV-positive and three confirmed
LASV-negative samples collected from suspected LF patients in Nigeria during the 2018 outbreak. Error bar indicates 95% confidence interval. f Results from
e were compared head-to-head to those from the gold standard Nikisins RT-qPCR assay, next-generation sequencing (genome assembled), and lateral flow
detection. g SHERLOCK testing using the LASV-IV assay of RNA extracted from seven confirmed LASV-positive and three confirmed LASV-negative samples
collected from suspected LF patients in Sierra Leone. Error bar indicates 95% confidence interval. h Results from g were compared head-to-head to those from









































































































Fig. 3 HUDSON safety testing. a Schematic overview of the HUDSON, SHERLOCK inactivation validation. Viral inactivation includes dilution with
EDTA : TCEP and a 20min 37 °C inactivation of nucleases. All final results were determined using lateral flow due to the inability to carry out
appropriate fluorescent analysis in the BSL4 facility. b Lateral flow detection of spiked blood, urine, and saliva inactivated at either 70 °C or 95 °C.
Serial dilution shown are PFU/mL. All assays were carried out in the BSL4 facility.
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difficult to interpret for low concentration samples due to the
correlation of band darkness with viral load. Critical for a
deployable rapid diagnostic and surveillance tool is an easy-to-use
interface that produces and reports a consistent readout free of
operator bias. In addition, lateral flow band strength has the
potential to generate a semi-quantitative result. To exploit that
potential and to facilitate accurate readout, we developed a mobile
phone application called HandLens that captures (Fig. 4a, b) and
analyzes (Fig. 4c–e) an image of one or more lateral flow strips to
quantify test results and resolve ambiguous readouts (Fig. 4).
Using a prototype version of the HandLens app, we tested a
dilution series (ranging from 105 to 10 copies/µl) from four
EBOV samples and compared our results to RT-qPCR. This
yielded estimates of 93% accuracy, 91% sensitivity, and 100%
specificity from a total of 21 strips (Supplementary Fig. 3a). This
app can be adapted for use on any smartphone or tablet, allowing
a clear, unbiased diagnostic readout.
Discussion
The recent severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pandemic has highlighted the need for rapid
deployable diagnostics that decrease healthcare worker exposure.
Although there has been great improvement with platforms like
Abbot and GeneXpert, these RT-qPCRs still require expensive
machines and laboratory infrastructure. Furthermore, this pan-
demic and other recent viral outbreaks have demonstrated the lag
time it takes to create a sensitive antibody- or antigen-based rapid
diagnostic test (RDT). SHERLOCK provides an alternative viral
diagnostic method that addresses these shortcomings. In sum-
mary, we have developed sensitive, specific, point-of-care CRISPR-
based diagnostics for EBOV and LASV, two hemorrhagic fever
viruses that pose immediate global threats. We have validated
these diagnostics on laboratory and patient samples, including
deployment for testing in partner laboratories in Sierra Leone and



















Fig. 4 Quantification of SHERLOCK lateral flow strips using HandLens, an Android app prototype. Internal image analysis pipeline of the SHERLOCK
detector app (HandLens). a Images of two positive sample lateral flow strips are imported to the app. b The relevant signal regions of the lateral flow strips
are detected and demarcated by red bounding boxes. c Bilateral filtering is used to extract and smoothen the signal regions from the raw input image.
d Contrast within the image is increased by applying contrast limited adaptive histogram equalization (CLAHE). e The signal is linearized for downstream
signal processing; the red curves indicate the signal extracted after applying CLAHE, whereas the blue curves indicate the signal levels if the CLAHE step is
skipped. f The strip reader app works by allowing the user to take a picture of the test strips where a rectangle can be used to select the control strip on the
leftmost side. The raw image data is sent to a backend server that runs the signal detection algorithm and returns the binary and semi-quantitative
predictions for each strip.
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not only removes the need for extraction but also inactivates
EBOV to allow for a safe low-tech test, and we demonstrated that
non-invasive samples including saliva and urine can be used for
rapid detection, eliminating the need for a blood draw and
increasing safety for clinical staff testing for suspected VHF. We
provide a user-friendly readout that can be documented using a
mobile device to allow for greater reproducibility and immediate
reporting. The HUDSON-SHERLOCK assay minimizes testing
time and handling of infectious samples, reduces the cost to less
than $1 USD29 per sample, and can be run with minimal equip-
ment using only solar power or a small generator to allow for
quick diagnostics in any environment, showcasing the growing
capabilities of CRISPR-based diagnostics for viral detection.
Methods
Ethical approval for the use of clinical samples. All patient samples used for this
study were de-identified and were obtained through studies that were evaluated
and approved by the institutional review boards at the Irrua Specialist Teaching
Hospital (Irrua, Nigeria), Redeemer’s University (Nigeria), KGH (Sierra Leone),
Sierra Leone Ministry of Health, Ministry of Health of the DRC, and Harvard
University (Cambridge, Massachusetts).
LF patients were recruited for this study using protocols approved by human
subjects committees at Harvard University, Broad Institute, Irrua Specialist
Teaching Hospital, KGH, Oyo State Ministry of Health, Ibadan, Nigeria, and Sierra
Leone Ministry of Health. All patients were treated with a similar standard of care
and were offered the drug Ribavirin, whether or not they decided to participate in
the study.
Due to the severe outbreak for EVD, patients could not be consented through
our standard protocols. Instead use of clinical excess samples from EVD patients
was evaluated and approved by Institutional Review Boards in Sierra Leone and at
Harvard University. The Office of the Sierra Leone Ethics and Scientific Review
Committee, the Sierra Leone Ministry of Health and Sanitation, and the Harvard
Committee on the Use of Human Subjects have granted a waiver of consent to use
de-identified samples collected from all suspected EVD patients receiving care
during the outbreak response. The Sierra Leone Ministry of Health and Sanitation
also approved shipments of non-infectious non-biological samples from Sierra
Leone to the Broad Institute and Harvard University for genomic studies of
outbreak samples.
Protocol Title: Genomic Characterization and Surveillance of Microbial Threats
in West Africa
Principal Investigator: Pardis C. Sabeti
Protocol #: IRB19-0023
Funding Source: The Broad Institute-5700161-5500000755 (Active), NIH;
Military HIV Research Program and Henry M. Jackson Foundation, NIH; Bill
and Melinda Gates Foundation
Protocol Title: Sierra Leone Lassa and Ebola Case Control (includes Ebola
Clinical Excess from Deceased Patients), Nigeria Lassa Case Control
Protocol #: CUHS 21288 and ORSP 2202
Harvard University
Funding Source: The Broad Institute-5700161-5500000755 (Active), NIH;
Military HIV Research Program and Henry M. Jackson Foundation, NIH; Bill
and Melinda Gates Foundation
Sample preparation. Patient samples were taken by clinical staff using appropriate
personal protective equipment. Inactivation of samples occurred in their country of
origin. Samples were then shipped to the Broad Institute or tested at the local
center (Nigeria, Sierra Leone). Samples were inactivated in AVL buffer (Qiagen) or
TRIzol (Life Technologies) following standard operating procedures. Samples were
stored in liquid nitrogen or at −20 °C. RNA was isolated at the clinical site using
the QIAamp Viral RNA Minikit (Qiagen) according to the manufacturer’s pro-
tocol. Poly(rA) and host rRNA were depleted using RNase H selective depletion,
using 616 ng oligo (dT) (40 nt long) and/or 1000 ng DNA probes complementary
to human rRNA. Samples then underwent RNase-free DNase using a kit (Qiagen)
according to the manufacturer’s protocol. AMPure RNA clean beads (Beckman
Coulter Genomics) were used to clean and concentrate samples. cDNA synthesis
was performed using the Superscript III kit (Thermo Fischer) plus dNTPs, random
primers, and SUPERASE-IN for first-strand synthesis. Then, the 10× second-
strand buffer kit (New England Biolabs), plus Escherichia coli DNA ligase, E. coli
DNA polymerase, Rnase H, and dNTPs were used for second-strand synthesis.
Samples then underwent a final AMpure DNA beads clean-up30.
SHERLOCK assay design. To design RPA primers and crRNAs, we identified
conserved regions of the EBOV and LASV genomes. For the EBOV assay, we used
an alignment based on all published sequences. The highly conserved areas of the
EBOV genome allowed us to design numerous efficient crRNAs, with two targeting
the NP-gene and two targeting the L gene (Supplementary Fig. 4a), neither of
which is expected to cross-react with the live attenuated vaccine. We developed an
EBOV assay using the most efficient crRNA based on peak fluorescence and
minimum time required for SHERLOCK detected to reach saturation (Supple-
mentary Fig. 4b). For the LASV-IV assay, we used an alignment based on all
published LASV clade IV sequences (Sierra Leone)21. For the LASV-II assay, we
used an alignment based on all published LASV clade II sequences (Nigeria)21,22.
We then used a 50 bp sliding window to identify flanking conserved areas. We
identified 21–29 bp primers and a 29 bp crRNA for the LASV-IV assay (Fig. 2a).
Due to the high diversity in clade II, one crRNA, even with up to six degenerate
bases, did not encompass all known genomes. We identified three crRNAs within
the same 200 bp region and tested these in tandem (Fig. 2b).
RPA reactions. All RPA reactions were carried out using the Twist-Dx RT-RPA kit
according to the manufacturer’s instructions. All reactions were run for 20 min.
Primer concentrations were 480 nM. For reactions with RNA input, Murine RNase
inhibitor (NEB M3014L) was added at a concentration of 2 units/µl. For a complete
list of RPA primer names and sequences, see Supplementary Table 1.
Production of LwaCas13a and crRNAs. LwaCas13a was purified by Genscript.
The crRNAs were determined by aligning all known genomes and using our
CATCH method19 to identify conserved areas on a sliding scale and were syn-
thesized by Integrated DNA Technologies.
CAS13a detection reactions. For detection reaction, refer to our one-page user-
friendly protocol (Supplementary Fig. 2). Detection assays were performed for
either plate reader (fluorescent) or lateral flow detection. Broadly, Cas13a, crRNas,
T7 polymerase (New England Biolabs), RNasae inhibitors (New England Biolabs),
buffer (CB—40 mM Tris-HCl, 60 mM NaCl, 6 mM MgCl2, pH 7.3), MgCl2 (rNTPs
(New England Biolabs), and either a fluorescent substrate reporter (RNase alert v2)
or LP probe (Tewist-Dx) were combined. Detection mix was combined with the
RPA reaction and incubator for 1 h at 37 °C13,14. For multiplexed crRNAs in
LASV-II assays, the total volume of crRNA was doubled. Reactions were run on a
Biotek Cytation 5 multi-mode reader. All reactions were run in triplicate alongside
a no-template control. Fluorescence kinetics were measured via a monochrometer
with excitation at 485 nm and emission at 520 nm, with a reading every 5 min.
EBOV assays were run for 1 h and LASV assays were run for 3 h. Reported
fluorescence values are specified as background-subtracted or template-specific. For
EBOV detection, the crRNA EBOVA was used unless otherwise noted. For
detection of LASV clade IV, the crRNA LASV-IVA was used. For detection of
LASV-II, an equal mix of crRNAs LASV-IIA and LASV-IIB was used. For a
complete list of crRNA names and sequences, see Supplementary Table 2.
Lateral flow detection reactions. Lateral flow detection reactions were performed
as described using commercially available detection strips according to manu-
facturer’s instructions (Milenia Hybridetect 1, Twist-Dx, Cambridge, UK).
Data analysis. For all fluorescence values, background-subtracted fluorescence was
calculated by subtracting the minimum fluorescence value, which occurred between
0–20min, from the final fluorescence value. For all fluorescence values reported for
patient samples, found in Figs. 1e, g and 2b, e, h, target-specific fluorescence was
calculated by subtracting the mean background-subtracted fluorescence of the no
template control from the mean background-subtracted fluorescence of a given
target with the same crRNA at the same time point.
LOD experiments. To determine the sensitivity of SHERLOCK assays, assay-
specific synthetically derived DNA templates were derived from clade- and virus-
specific alignments1,17,20–22. Synthetically derived DNA (≤500 bp and non-
replicant competent) templates were used as input into the RPA reaction at con-
centrations from 104 copies/µl to 1 copy/µl with a 1 : 10 dilution series. Each
crRNA was also tested on a no-input negative control. Reactions were run twice,
using both the fluorescent readout and the lateral flow readout. All reactions were
run in triplicate for the fluorescent readout.
Cross-reactivity experiments. To assess the cross-reactivity of assays with other
viruses known to cause hemorrhagic symptoms, all assays were tested on LASV
(Josiah), EBOV (Makona), and MARV (Angola) viral cDNA seed stocks. Each assay
was also tested on a positive control containing an assay-specific synthetically derived
DNA template at a concentration of 104 copies/µl and on no-input negative control.
Synthetically derived DNA were short fragments that encompassed the primers and
around 20 base pairs on both the 5′- and 3′-end. All fragments were non-replicant
competent. All reactions were run in triplicate. The LASV assays were also assessed
for clade-specific detection. The LASV-IV assay was tested on three RNA patient
samples from clade II and the LASV-II assay was tested on three RNA patient
samples from clade IV. Each assay was also tested on a positive control containing an
assay-specific synthetically derived DNA template at a concentration of 104 copies/µl
and on no-input negative control. All reactions were run in triplicate.
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Validation on patient samples. The LASV-IV assay was validated on a panel of 12
RNA samples collected from suspected LF patients in Sierra Leone21,22. Seven of
these samples were confirmed LASV positive by antigen-based RDT, enzyme-
linked immunosorbent assay (ELISA) IgM, and RT-qPCR31; four were confirmed
LASV negative by RDT, ELISA, and RT-qPCR; one did not have the full panel of
tests. The assay was also tested on a positive control containing synthetically
derived cDNA and a no-input control. All reactions were run in triplicate. A subset
of these samples was tested using the lateral flow readout. Results were compared to
RT-qPCR results and sequencing results. The LASV-II assay was validated on a
panel of 12 cDNA samples collected from suspected LF patients in Nigeria during
the 2018 outbreak22. Nine of these samples were confirmed LASV positive and
three were confirmed LASV negative. The assay was also tested on a positive
control containing synthetically derived cDNA at a concentration of 104 cp/µl and
a no-input control. All reactions were run in triplicate. A subset of these samples
was also tested using the lateral flow readout. Results were compared to RT-qPCR
results and sequencing results.
The EBOV assay was validated on a panel of 16 cDNA and RNA samples
collected from suspected EVD patients in Sierra Leone during the 2014
outbreak17,20. Twelve of these samples were confirmed EBOV positive and four
were confirmed EBOV negative. The assay was also tested on a positive control
containing synthetically derived cDNA at a concentration of 104 cp/µl and a no-
input control. All reactions were run in triplicate. To validate the lateral flow
readout, the EBOV assay was tested on four EBOV-positive cDNA samples,
alongside a positive and a no-input control.
RT-qPCR experiments. RT-qPCR for LASV detection was performed using the
Power SYBR Green RNA-to-Ct 1-step RT-qPCR kit (Thermo Fisher) according
to the manufacturer’s instructions. Reactions were performed on a LightCycler
96 machine (Roche). For detection of LASV clade II, the primers Nikisins_F and
Nikisins_R were used25. For detection of LASV clade IV, the in-house assay,
including primers Broad_F and Broad_R, was also used with the TaqMan RNA-to-
CT 1-Step Kit (Applied Biosystems). For a complete list of primer names and
sequences, see Supplementary Table 4; for a complete list of probe names and
sequences, see Supplementary Table 5.
EBOV DRC experiments. All samples tested at USAMRIID underwent SHER-
LOCK as described above with the exception of the fluorescent readout which was
conducted on a BioRad CFX96. The genomes of both the Makona and Ituri isolates
were sequenced with Illumina technology (MiSeq for Makona and iSeq for Ituri)
in-country as described in ref. 24. Briefly, once the genome sequences were
obtained, sub-genomic fragments were commercially synthesized and then
assembled into plasmids encoding full genomes at USAMRIID. The RNAs were
in vitro transcribed from the full genome plasmids. All SHERLOCK work on these
isolates was carried out at USAMRIID.
Safety testing of HUDSON and SHERLOCK. Before inactivation all samples
should be treated using BSL4 safety conditions. All clinical and laboratory staff
should wear full PPE and/or use a glove box to acquire and handle patient samples.
We also recommend that all equipment should be decontaminated before and after
each use. Samples remain highly infectious until the full heat inactivation protocol
can be carried out.
Viral titers for each sample were determined by plaque assay; a six-well plate with
a confluent monolayer of VeroE6 cells was infected with a predetermined volume of
sample. The wells are then overlaid with a medium to ensure the monolayer health
and incubated for a set amount of time. If there is live virus in the sample, this virus
will infect and kill a cell, and spread cell-to-cell creating a plaque, or a clearing of cells.
Plaques are then visualized by a crystal violet stain and counted to determine viral
titer. Samples underwent a serial dilution and then were heat-inactivated using
methods described in14. Briefly, a 1 : 100 solution of 0.5M EDTA to TCEP (Thermo)
was used to decrease RNase degradation. The EDTA : TCEP was added to spiked
samples at a ratio of one part EDTA : TCEP to four parts samples. First, samples were
heated to 37 °C for 20min to inactivate nucleases. The samples were then heated to
95 °C for 10min or 70 °C for 30min as described, followed by the SHERLOCK assay
as described above. Only Eppendorph Safe-Lock tubes or cryovials with a screw top
should be used for heat inactivation and the outside of the tubes should be
decontaminated before and after heat inactivation.
The samples then underwent primary passaging. Samples were added to a T25
flask, incubated for 1 h at 37 °C at 5% CO2, then replenished with media and
incubated for 7 days. Seven days post infection (dpi) pictures were taken of each
flask to assess for cytopathic effect. Secondary passage was performed to assess for
any residual virus particles not detected in the primary passage. All media was
transferred from the T25 flask to a T75 flask incubated for 1 h at 37 °C at 5% CO2,
replenished with media and incubated for 7 dpi, and then photographed. Following
the primary and secondary passaging, a final plaque assay was performed to
determine viral titer and to assess viral clearance or reduction. For diagnostic
comparison, qPCR samples were run on the Cepheid GeneXpert platform. Sample
were inactivated in Xpert lysis buffer at room temperature for 10 min and then run
with an Xpert Ebola assay cartridge10.
HandLens: the lateral flow reader app. First, the signal-containing section of the
lateral flow strip is detected using OpenCV’s32 contour detection routines. This
region is extracted and transformed into a smooth two-dimensional image using
bilateral filtering. The result is enhanced using contrast limited adaptive histogram
equalization33, which has the property of increasing signal contrast in local regions.
This signal is then linearized by integrating pixel intensity over each row. Finally, a
signal is marked as positive for viral load if the signal intensity in the test band of
the strip is above a certain user-defined threshold compared to the control strip,
and negative if the signal intensity is too low. We also developed quantifiable signal
graphs of each band and controlled for shadows and image contrast by applying a
contrast-improvement algorithm (Supplementary Fig. 3b).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data presented in this manuscript and generated for this work are included in the
written text and figures including a list of all RPA primer sequences (Supplementary
Table 1), crRNA spacer sequences (Supplementary Table 2), RT-qPCR primer sequences
(Supplementary Table 4), and RT-qPCR probe sequences (Supplementary Table 5). All
results generated using a fluorescence readout are the average of three replicates. Any
other relevant data are available from the authors upon reasonable request. Source data
are provided with this paper.
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